SMTL ID : 4c8b.1

Structure of the kinase domain of human RIPK2 in complex with ponatinib

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 2.75 Å

Oligo State

homo-dimer

Ligands

2 x 0LI: 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzam ide(Non-covalent)

0LI.1: 20 residues within 4Å: Chain A: V.49, A.62, V.63, K.64, E.83, L.87, I.95, L.96, I.110, T.112, E.113, Y.114, M.115, L.160, H.161, L.170, I.179, A.180, D.181, F.182 15 PLIP interactions: 15 interactions with chain A Hydrophobic interactions: A:K.64, A:E.83, A:L.87, A:L.87, A:L.96, A:I.110, A:T.112, A:D.181, A:F.182 Hydrogen bonds: A:E.83, A:E.83, A:M.115, A:D.181 Salt bridges: A:D.181 Halogen bonds: A:I.179 0LI.3: 19 residues within 4Å: Chain B: A.62, V.63, K.64, E.83, L.87, I.95, L.96, I.110, T.112, E.113, Y.114, M.115, L.160, H.161, L.170, I.179, A.180, D.181, F.182 14 PLIP interactions: 14 interactions with chain B Hydrophobic interactions: B:A.62, B:K.64, B:K.64, B:E.83, B:L.87, B:L.96, B:T.112, B:D.181, B:F.182 Hydrogen bonds: B:E.83, B:M.115, B:D.181 Salt bridges: B:D.181 Halogen bonds: B:I.179

1 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)

EDO.2: 5 residues within 4Å: Chain A: W.135, R.138, L.240, S.241, R.242 3 PLIP interactions: 3 interactions with chain A Hydrogen bonds: A:R.138, A:R.138, A:L.240

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Canning, P. et al., Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors. Chem. Biol. (2015)

Release Date

2013-10-16

Peptides

RECEPTOR-INTERACTING SERINE/THREONINE-PROTEIN KINASE 2: AB

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
B

RECEPTOR-INTERACTING SERINE/THREONINE-PROTEIN KINASE 2